Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment - Reviews in Endocrine and Metabolic Disorders
Source : https://link.springer.com/article/10.1007/s11154-022-09774-1
Phase angle (PhA) is a recently proposed marker of nutritional status in many clinical conditions. Its use in patients with obesity presents different critical concerns due to the higher variability...
Conclusion: We can conclude that the PhA could be used as marker of health status in patients with obesity supporting an appropriate weight loss intervention to monitor efficacy and fat free mass preservation.
Share
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Source : https://www.hindawi.com/journals/cdtp/2022/6820377/
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been observed in several large cardiovascular outcome trials to significantly reduce the incidence of major cardiovascular event (MACE) with type 2 diabetic...
Conclusions/Relevance: The focus of the review is on GLP-1 RAs’ preventive roles in nondiabetic individuals with cardiovascular disease, chronic kidney diseases, obesity, dyslipidaemia, hypertension, nonalcoholic fatty liver diseases, polycystic ovarian syndrome (PCOS), and perioperative complications of bariatric surgery, albeit in small...
Share
Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36480511/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: GH supplementation did not augment the anti-diabetic effects of liraglutide.
Share